Online inquiry

IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12271MR)

This product GTTS-WQ12271MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Systemic sclerosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12271MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4293MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ12038MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ7669MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ2213MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ8795MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ8910MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ10116MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ12213MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOXR-0916
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW